374. Gogas H., Bafaloukos D., Ioannovich J., Skarlos D., Polyzos A., Fountzilas G., Kalofonos H. P., Aravantinos G., Tsoutsos D., Panagiotou P., Frangia K., Petrakopoulou T., Pectasides D. Tolerability of adjuvant high-dose interferon alfa-2b: 1 month versus 1 year--a Hellenic Cooperative Oncology Group study // Anticancer Res. ‒ 2004. ‒ T. 24, № 3b. ‒ C. 1947-52.
375. Hauschild A., Gogas H., Tarhini A., Middleton M. R., Testori A., Dreno B., Kirkwood J. M. Practical guidelines for the management of interferon-alpha-2b side effects in patients receiving adjuvant treatment for melanoma: expert opinion // Cancer. ‒ 2008. ‒ T. 112, № 5. ‒ C. 982-94.
376. Trotti A., Colevas A. D., Setser A., Rusch V., Jaques D., Budach V., Langer C., Murphy B., Cumberlin R., Coleman C. N., Rubin P. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment // Semin Radiat Oncol. ‒ 2003. ‒ T. 13, № 3. ‒ C. 176-81.
377. Mohr P., Hauschild A., Enk A., Trefzer U., Rass K., Grabbe S., Brockmeyer N. H., Koller J., Gogas H., Weichenthal M. Intermittent high-dose intravenous interferon alpha 2b (IFNa2b) for adjuvant treatment of stage III malignant melanoma: An interim analysis of a randomized phase III study (NCT00226408). // J Clin Oncol. ‒ 2008. ‒ T. 26, № suppl.
378. Veronesi U., Adamus J., Aubert C., Bajetta E., Beretta G., Bonadonna G., Bufalino R., Cascinelli N., Cocconi G., Durand J., De Marsillac J., Ikonopisov R. L., Kiss B., Lejeune F., MacKie R., Madej G., Mulder H., Mechl Z., Milton G. W., Morabito A., Peter H., Priario J., Paul E., Rumke P., Sertoli R., Tomin R. A randomized trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma // N Engl J Med. ‒ 1982. ‒ T. 307, № 15. ‒ C. 913-6.
379. Balch C. M., Murray D., Presant C., Bartolucci A. A. Ineffectiveness of adjuvant chemotherapy using DTIC and cyclophosphamide in patients with resectable metastatic melanoma // Surgery. ‒ 1984. ‒ T. 95, № 4. ‒ C. 454-9.
380. Tranum B. L., Dixon D., Quagliana J., Neidhart J., Balcerzak S. P., Costanzi J. H., Fabian C. J., Neilan B., Maloney T., O'Bryan R. M., et al. Lack of benefit of adjunctive chemotherapy in stage I malignant melanoma: a Southwest Oncology Group Study // Cancer Treat Rep. ‒ 1987. ‒ T. 71, № 6. ‒ C. 643-4.
381. Saba H. I., Cruse C. W., Wells K. E., Klein C. J., Reintgen D. S. Adjuvant chemotherapy in malignant melanoma using dacarbazine, carmustine, cisplatin, and tamoxifen: a University of South Florida and H. Lee Moffitt Melanoma Center Study // Ann Plast Surg. ‒ 1992. ‒ T. 28, № 1. ‒ C. 60-4.
382. Stables G. I., Doherty V. R., MacKie R. M. Nine years' experience of BELD combination chemotherapy (bleomycin, vindesine, CCNU and DTIC) for metastatic melanoma // Br J Dermatol. ‒ 1992. ‒ T. 127, № 5. ‒ C. 505-8.
383. Karakousis C., Blumenson L. Adjuvant chemotherapy with a nitrosourea-based protocol in advanced malignant melanoma // Eur J Cancer. ‒ 1993. ‒ T. 29A, № 13. ‒ C. 1831-5.
384. Pectasides D., Alevizakos N., Bafaloukos D., Tzonou A., Asimakopoulos G., Varthalitis I., Dimitriadis M., Athanassiou A. Adjuvant chemotherapy with dacarbazine, vindesine, and cisplatin in pathological stage II malignant melanoma // Am J Clin Oncol. ‒ 1994. ‒ T. 17, № 1. ‒ C. 55-9.
385. Garbe C., Radny P., Linse R., Dummer R., Gutzmer R., Ulrich J., Stadler R., Weichenthal M., Eigentler T., Ellwanger U., Hauschild A. Adjuvant low-dose interferon {alpha}2a with or without dacarbazine compared with surgery alone: a prospective-randomized phase III DeCOG trial in melanoma patients with regional lymph node metastasis // Ann Oncol. ‒ 2008. ‒ T. 19, № 6. ‒ C. 1195-201.
386. Kleeberg U. R., Suciu S., Brocker E. B., Ruiter D. J., Chartier C., Lienard D., Marsden J., Schadendorf D., Eggermont A. M. Final results of the EORTC 18871/DKG 80-1 randomised phase III trial. rIFN-alpha2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness >3 mm) or regional lymph node metastasis // Eur J Cancer. ‒ 2004. ‒ T. 40, № 3. ‒ C. 390-402.
387. Marjanska A., Galazka P., Marjanski M., Wysocki M., Styczynski J. Efficacy and Toxicity of Pembrolizumab in Pediatric Metastatic Recurrent Melanoma // Anticancer Res. ‒ 2019. ‒ T. 39, № 7. ‒ C. 3945-3947.
388. Luke J. J., Rutkowski P., Queirolo P., Del Vecchio M., Mackiewicz J., Chiarion-Sileni V., de la Cruz Merino L., Khattak M. A., Schadendorf D., Long G. V., Ascierto P. A., Mandala M., De Galitiis F., Haydon A., Dummer R., Grob J. J., Robert C., Carlino M. S., Mohr P., Poklepovic A., Sondak V. K., Scolyer R. A., Kirkwood J. M., Chen K., Diede S. J., Ahsan S., Ibrahim N., Eggermont A. M. M., Investigators K.-. Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial // Lancet. ‒ 2022. ‒ T. 399, № 10336. ‒ C. 1718-1729.
389. Navid F., Furman W. L., Fleming M., Rao B. N., Kovach S., Billups C. A., Cain A. M., Amonette R., Jenkins J. J., Pappo A. S. The feasibility of adjuvant interferon alpha-2b in children with high-risk melanoma // Cancer. ‒ 2005. ‒ T. 103, № 4. ‒ C. 780-7.
390. Navid F., Herzog C. E., Sandoval J., Daryani V. M., Stewart C. F., Gattuso J., Mandrell B., Phipps S., Chemaitilly W., Sykes A., Davidoff A. M., Shulkin B. L., Bahrami A., Furman W. L., Mao S., Wu J., Schiff D., Rao B., Pappo A. Feasibility of Pegylated Interferon in Children and Young Adults With Resected High-Risk Melanoma // Pediatr Blood Cancer. ‒ 2016. ‒ T. 63, № 7. ‒ C. 1207-13.
391. Kirkwood J. M., Manola J., Ibrahim J., Sondak V., Ernstoff M. S., Rao U., Eastern Cooperative Oncology G. A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma // Clin Cancer Res. ‒ 2004. ‒ T. 10, № 5. ‒ C. 1670-7.